100 Recruiting Studies Using Azacitidine
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Azacitidine
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
📍 Banner MD Anderson — Gilbert, Arizona
Leukemia, Myeloid, Acute
View Study & Checklist ➔A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
📍 City of Hope /ID# 154105 — Duarte, California
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
📍 Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
Acute Myeloid Leukemia
View Study & Checklist ➔A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
📍 City of Hope National Medical Center — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 Children's Hospital of Central California — Madera, California
Acute Myeloid Leukemia
View Study & Checklist ➔Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Myelomonocytic Leukemia-0
View Study & Checklist ➔Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
📍 City of Hope National Medical Center /ID# 269273 — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
📍 City of Hope — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
📍 City of Hope — Duarte, California
Leukemia, Myeloid, Acute
View Study & Checklist ➔Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
📍 Local Institution - 105 — Duarte, California
Leukemia, Myeloid, Acute
View Study & Checklist ➔A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
📍 University of California, Los Angeles — Los Angeles, California
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
📍 City of Hope Nat'l Medical Center — Duarte, California
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
📍 University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Acute Erythroid Leukemia
View Study & Checklist ➔A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
📍 The University of Alabama at Birmingham — Birmingham, Alabama
Leukemia, Myeloid, Acute
View Study & Checklist ➔Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Secondary Myelodysplastic Syndrome
View Study & Checklist ➔Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Osteosarcoma
View Study & Checklist ➔Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
📍 Northwestern University — Chicago, Illinois
Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
View Study & Checklist ➔Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
📍 City of Hope National Medical Center — Duarte, California
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
📍 O'Neal Comprehensive Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
📍 Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
Acute Myeloid Leukemia
View Study & Checklist ➔Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
📍 MD Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
📍 Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Adult Nasal Type Extranodal NK/T-Cell Lymphoma
View Study & Checklist ➔AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia in Remission
View Study & Checklist ➔Cladribine Venetoclax in Monocytic AML
📍 Universtiy of Colorado Hospital — Aurora, Colorado
Acute Myeloid Leukemia
View Study & Checklist ➔Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Leukemia
View Study & Checklist ➔Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
📍 Oregon Health Sciences University — Portland, Oregon
Myelodysplastic Syndromes
View Study & Checklist ➔Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
📍 Norton Cancer Institute - Suburban — Louisville, Kentucky
Newly Diagnosed Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
📍 Universtiy of Colorado Denver — Aurora, Colorado
High Grade Myelodysplastic Syndromes
View Study & Checklist ➔Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
📍 Johns Hopkins All Children's Hospital — St. Petersburg, Florida
Acute Myeloid Leukemia
View Study & Checklist ➔Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
📍 Duplicate_Providence Medical Foundation /ID# 222633 — Fullerton, California
Myelodysplastic Syndrome (MDS)
View Study & Checklist ➔Pilot Study of Reduced Venetoclax Exposure
📍 Zuckerberg Cancer Center — New Hyde Park, New York
Acute Myeloid Leukemia in Remission
View Study & Checklist ➔A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
📍 City of Hope — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
📍 MD Anderson Cancer Center — Houston, Texas
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
📍 M D Anderson Cancer Center — Houston, Texas
Acute Bilineal Leukemia
View Study & Checklist ➔Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
📍 Roswell Park Comprehensive Cancer Center — Buffalo, New York
Myeloproliferative Neoplasm
View Study & Checklist ➔Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
📍 Virginia Commonwealth University — Richmond, Virginia
Relapsed / Refractory AML
View Study & Checklist ➔Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Recurrent Anaplastic Large Cell Lymphoma
View Study & Checklist ➔Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
📍 Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina
Leukemia Acute Myeloid
View Study & Checklist ➔A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
📍 City of Hope — Duarte, California
AML (Acute Myeloid Leukemia)
View Study & Checklist ➔Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
📍 Houston Methodist Neal Cancer Center — Houston, Texas
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations
📍 MD Anderson Cancer Center — Houston, Texas
Ropeginterferon
View Study & Checklist ➔A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
📍 University of Alabama at Birmingham — Birmingham, Alabama
Myelodysplastic Syndrome
View Study & Checklist ➔A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
📍 Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Acute Myeloid Leukemia
View Study & Checklist ➔A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
📍 Mayo Clinic - Phoenix — Phoenix, Arizona
Acute Myeloid Leukemia
View Study & Checklist ➔Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
📍 Moffitt Cancer Center — Tampa, Florida
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
📍 University of Alabama at Birmingham — Birmingham, Alabama
Leukemia, Myeloid, Acute
View Study & Checklist ➔A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
📍 Brigham and Women's Hospital — Boston, Massachusetts
Acute Myeloid Leukaemia (AML)
View Study & Checklist ➔Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
📍 University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Acute Monocytic Leukemia
View Study & Checklist ➔Ascorbate in Myelodysplastic Syndrome
📍 University of Iowa — Iowa City, Iowa
Myelodysplastic Syndromes
View Study & Checklist ➔Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
📍 The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Leukemia, Myeloid, Acute
View Study & Checklist ➔IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
📍 University of Colorado — Aurora, Colorado
Acute Myeloid Leukemia
View Study & Checklist ➔Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
📍 The University of Chicago — Chicago, Illinois
Chronic Myeloid Leukemia
View Study & Checklist ➔A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
📍 MD Anderson Cancer Center — Houston, Texas
Myelodysplastic Syndrome(MDS)
View Study & Checklist ➔BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
📍 University of Illinois Cancer Center — Chicago, Illinois
Breast Cancer Invasive
View Study & Checklist ➔Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Acute Myeloid Leukemia
View Study & Checklist ➔A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
📍 Keck School of Medicine of USC — Los Angeles, California
Myelodysplastic Syndromes
View Study & Checklist ➔Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
📍 Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Acute Myeloid Leukemia
View Study & Checklist ➔Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
📍 Mayo Clinic Arizona — Phoenix, Arizona
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
View Study & Checklist ➔A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
📍 Moffitt Cancer Center — Tampa, Florida
Myelodysplastic Syndrome
View Study & Checklist ➔A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
📍 UCLA Ronald Reagan Medical Center — Los Angeles, California
Higher-risk Myelodysplastic Syndromes
View Study & Checklist ➔A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
📍 Phoenix Children's Hospital — Phoenix, Arizona
Leukemia, Juvenile Myelomonocytic
View Study & Checklist ➔Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
View Study & Checklist ➔Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
📍 M D Anderson Cancer Center — Houston, Texas
Acute Bilineal Leukemia
View Study & Checklist ➔Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
📍 Atrium Health Wake Forest Baptist Medical Center — Winston-Salem, North Carolina
IDH1 Mutation
View Study & Checklist ➔Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Acute Myeloid Leukemia
View Study & Checklist ➔APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
📍 Colorado Blood Cancer Institute — Denver, Colorado
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Atypical Chronic Myeloid Leukemia
View Study & Checklist ➔Pacritinib in CMML
📍 The Mount Sinai Hospital — New York, New York
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
📍 University of Iowa Health Care — Iowa City, Iowa
Acute Myeloid Leukemia
View Study & Checklist ➔A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
📍 City of Hope Medical Center — Duarte, California
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
📍 University of Colorado Hospital — Aurora, Colorado
Leukemia
View Study & Checklist ➔Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Haematological Malignancy
View Study & Checklist ➔Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
📍 UCSF-Fresno — Clovis, California
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax Basket Trial for High Risk Hematologic Malignancies
📍 University of California San Francisco-Benioff Children's Hospital — San Francisco, California
Myelodysplastic Syndromes, de Novo
View Study & Checklist ➔Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
📍 Presbyterian / St. Luke'S Medical Center — Denver, Colorado
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
View Study & Checklist ➔Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
📍 OHSU Knight Cancer Institute — Portland, Oregon
Acute Myeloid Leukemia
View Study & Checklist ➔Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
📍 Rady Children's Hospital — San Diego, California
Refractory Acute Myeloid Leukemia
View Study & Checklist ➔Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
📍 University of Miami — Miami, Florida
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Acute Myeloid Leukemia
View Study & Checklist ➔A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
📍 M D Anderson Cancer Center — Houston, Texas
Myelodysplastic Syndromes
View Study & Checklist ➔Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
📍 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Myelodysplastic Syndromes
View Study & Checklist ➔Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
📍 Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
📍 Case Western Reserve University — Cleveland, Ohio
Acute Myeloid Leukemia
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
📍 City of Hope National Medical Center /ID# 279568 — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
📍 MD Anderson Cancer Center — Houston, Texas
Higher-risk Myelodysplastic Syndrome
View Study & Checklist ➔Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
📍 Children's Hospital Los Angeles — Los Angeles, California
Hematologic Malignancy
View Study & Checklist ➔Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
📍 OHSU Knight Cancer Institute — Portland, Oregon
Acute Myeloid Leukemia
View Study & Checklist ➔Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
📍 Brigham and Women's Hospital — Boston, Massachusetts
Leukemia, Myeloid
View Study & Checklist ➔Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
📍 City of Hope Medical Center — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
📍 MD Anderson Cancer Center — Houston, Texas
Refractory Acute Leukemia
View Study & Checklist ➔A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
📍 Hoag Family Cancer Center — Newport Beach, California
Leukemia, Myeloid, Acute
View Study & Checklist ➔ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
Acute Myelogenous Leukemia
View Study & Checklist ➔